3-benzyl-5-methyl-3H-imidazole-4-carboxylic acid ethyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-benzyl-5-methyl-3H-imidazole-4-carboxylic acid ethyl ester
• 英文别名: ethyl 3-benzyl-5-methyl-3H-imidazole-4-carboxylate；ethyl 1-benzyl-4-methyl-1H-imidazole-5-carboxylate；ethyl 3-benzyl-5-methylimidazole-4-carboxylate
• 化学式: C₁₄H₁₆N₂O₂
• 分子量: 244.293
• InChiKey: VMHZGTHFPOQSMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  溴甲苯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.5h， 以47%的产率得到1-苄基-5-甲基咪唑-4-羧酸乙酯
  参考文献：
  名称：

  1H-imidazole derivatives as cannabinoid CB2 receptor modulators

  摘要：

  该发明涉及一组1H-咪唑衍生物，它们是大麻素CB2受体调节剂，涉及制备这些化合物的方法，有用于合成该咪唑衍生物的新型中间体，制备这些中间体的方法，含有一种或多种这些1H-咪唑衍生物作为活性成分的药物组合物，以及将这些药物组合物用于治疗涉及大麻素CB2受体的疾病。这些化合物具有通式（I），其中R1-R4具有规范中给出的含义。

  公开号：

  US20060194779A1

文献信息

• One-Pot Synthesis of Imidazole-4-Carboxylates by Microwave-Assisted 1,5-Electrocyclization of Azavinyl Azomethine Ylides
  作者：Lisa Preti、Orazio A. Attanasi、Emilia Caselli、Gianfranco Favi、Claudia Ori、Paolo Davoli、Fulvia Felluga、Fabio Prati

  DOI：10.1002/ejoc.201000434

  日期：2010.8

  Diversely functionalized imidazole-4-carboxylates were synthesized by microwave-assisted 1,5-eletrocyclization of 1,2-diaza-1,3-diene-derived azavinyl azomethine ylides. 1,2-Diaza-1,3-dienes were treated with primary aliphatic or aromatic amines and subjected to microwave irradiation in the presence of aldehydes. 3-Alkyl- and 3-arylimidazole-4-carboxylates were prepared in good yields through a one-pot

  通过微波辅助1,2-二氮杂-1,3-二烯衍生的氮杂乙烯基偶氮甲亚胺的1,5-电环合成了功能不同的咪唑-4-羧酸酯。用伯脂族或芳族胺处理1,2-二氮杂-1,3-二烯，并在醛存在下进行微波辐射。通过一锅多组分方法以高收率制备了3-烷基-和3-芳基咪唑-4-羧酸酯。在C-2，N-3和C-5处取代基的调节是可能的，并且当使用低聚甲醛时获得了2-未取代的咪唑。
• Regioselective Alkylation of 2-Alkyl-5,6,7,8-tetrahydro-3H-cycloheptimidazol-4-ones and 2-Alkyl-3H-cycloheptimidazol-4-ones
  作者：Motoharu Sonegawa、Masayuki Yokota、Hiroshi Tomiyama、Tsuyoshi Tomiyama

  DOI：10.1248/cpb.54.706

  日期：——

  Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3H-cycloheptimidazol-4-one (1) and 2-alkyl-3H-cycloheptimidazol-4-one (2) was investigated. 3-[2′-(1-tert-Butyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2-propyl-5,6,7,8-tetrahydro-1H-cycloheptimidazol-4-one (6) was preferentially obtained under the conditions by using NaH in DMF or THF. On the other hand, 3-[2′-(1-tert-butyl-1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-2-propyl-5,6,7,8-tetrahydro-3H-cycloheptimidazol-4-one (5), the synthetic intermediate compound of Pratosartan, was obtained selectively in the presence of n-Bu4NBr in toluene by using aqueous sodium hydroxide as a base. In this reaction, it was found that the concentration of the alkaline solution influences its regioselectivity. This selectivity was observed even for aldehyde and ester derivatives.

  研究了2-烷基-5,6,7,8-四氢-3H-环庚咪唑-4-酮（1）和2-烷基-3H-环庚咪唑-4-酮（2）的区域选择性烷基化反应。在DMF或THF中使用NaH的条件下，优先得到3-[2′-(1-叔丁基-1H-四唑-5-基)联苯-4-基甲基]-2-丙基-5,6,7,8-四氢-1H-环庚咪唑-4-酮（6）。另一方面，在甲苯中使用水合氢氧化钠作为碱和n-Bu4NBr存在下，选择性得到3-[2′-(1-叔丁基-1H-四唑-5-基)联苯-4-基甲基]-2-丙基-5,6,7,8-四氢-3H-环庚咪唑-4-酮（5），即普拉托沙坦的合成中间体化合物。在这项反应中，发现碱性溶液的浓度影响其区域选择性。这种选择性甚至在醛和酯衍生物中也观察到。
• Imidazole guanidines, their preparation and compositions containing them
  申请人：Merck & Co., Inc.

  公开号：EP0020173B1

  公开（公告）日：1983-02-09
• 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
  申请人：Lange H.M. Josephus

  公开号：US20060194779A1

  公开（公告）日：2006-08-31

  The invention relates to a group of 1H-imidazole derivatives which are modulators of cannabinoid CB 2 receptors, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said imidazole derivatives, to methods for the preparation of these intermediates, to pharmaceutical compositions containing one or more of these 1H-imidazole derivatives as active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which cannabinoid CB 2 receptors are involved. The compounds have the general formula (I) wherein R 1 -R 4 have the meanings given in the specification.

  该发明涉及一组1H-咪唑衍生物，它们是大麻素CB2受体调节剂，涉及制备这些化合物的方法，有用于合成该咪唑衍生物的新型中间体，制备这些中间体的方法，含有一种或多种这些1H-咪唑衍生物作为活性成分的药物组合物，以及将这些药物组合物用于治疗涉及大麻素CB2受体的疾病。这些化合物具有通式（I），其中R1-R4具有规范中给出的含义。